This retrospective study included inpatients with schizophrenia admitted between January 2015 and April 2022. Patients met the diagnosis criteria of schizophrenia according to the International Classification of Diseases-10 (ICD-10) and received mECT treatment during their hospitalization. The diagnosis of HAP required all the following criteria: new lung infiltrates on chest imaging, respiratory decline, fever, and productive cough (37 (link)). Patients with infections within 48 h of hospitalization were excluded. This study was approved by the Ethics Committee of the Fourth People's Hospital of Chengdu.
Patient information collected included name, age, gender, as well as the status of diabetes mellitus, hypertension, epilepsy, or substance dependence (smoking or drinking), and excluded patients with comorbid cardiovascular disease. Blood samples were collected on admission for routine biochemical testing (white blood cells, red blood cells, platelets, lipids, glucose, blood proteins, etc.). Other medications of patients receiving mECT at the time of hospitalization were recorded, such as sedative-hypnotic drugs (SHD), antidepressant drugs (ADD), anti-anxiety drugs (AAD), antimanic drugs (AMD), anti-epileptic drugs (AED), anti-parkinsonian drugs (APD), and other neurological drugs. mECT-related conditions only for patients with HAP, such as the days from the first mECT to HAP (dfE2H) occurrence, the numbers of mECT treatments before HAP (nE2H) occurrence, and the days from the last mECT treatment to HAP (dlE2H) occurrence.
Patient information collected included name, age, gender, as well as the status of diabetes mellitus, hypertension, epilepsy, or substance dependence (smoking or drinking), and excluded patients with comorbid cardiovascular disease. Blood samples were collected on admission for routine biochemical testing (white blood cells, red blood cells, platelets, lipids, glucose, blood proteins, etc.). Other medications of patients receiving mECT at the time of hospitalization were recorded, such as sedative-hypnotic drugs (SHD), antidepressant drugs (ADD), anti-anxiety drugs (AAD), antimanic drugs (AMD), anti-epileptic drugs (AED), anti-parkinsonian drugs (APD), and other neurological drugs. mECT-related conditions only for patients with HAP, such as the days from the first mECT to HAP (dfE2H) occurrence, the numbers of mECT treatments before HAP (nE2H) occurrence, and the days from the last mECT treatment to HAP (dlE2H) occurrence.
Free full text: Click here
